|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Aerovate Therapeutics, Inc. (AVTE) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
27,670,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Aerovate Therapeutics is a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Co.'s initial focus is on improving AV-101, its dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. AV-101, delivered using a dry powder inhaler, is designed to provide lung concentrations at or above those observed with the oral dose while limiting systemic levels of the drug.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
208,525 |
256,733 |
356,732 |
1,097,676 |
Total Sell Value |
$5,419,001 |
$6,301,594 |
$7,926,646 |
$16,938,629 |
Total People Sold |
6 |
7 |
7 |
8 |
Total Sell Transactions |
25 |
36 |
50 |
113 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Dake Benjamin T |
See Remarks |
|
2022-09-07 |
4 |
AS |
$18.12 |
$67,469 |
D/D |
(3,663) |
0 |
|
- |
|
Dake Benjamin T |
See Remarks |
|
2022-09-07 |
4 |
OE |
$1.74 |
$14,303 |
D/D |
8,220 |
8,220 |
|
- |
|
Dake Benjamin T |
See Remarks |
|
2022-09-06 |
4 |
AS |
$17.94 |
$169,876 |
D/D |
(9,166) |
0 |
|
- |
|
Dake Benjamin T |
See Remarks |
|
2022-09-06 |
4 |
OE |
$1.74 |
$15,949 |
D/D |
9,166 |
9,166 |
|
- |
|
Niven Ralph |
Chief Scientific Officer |
|
2022-09-06 |
4 |
AS |
$19.00 |
$42,750 |
D/D |
(2,250) |
1,609 |
|
- |
|
Niven Ralph |
Chief Scientific Officer |
|
2022-09-06 |
4 |
OE |
$1.74 |
$4,555 |
D/D |
2,250 |
3,859 |
|
- |
|
Niven Ralph |
Chief Scientific Officer |
|
2022-08-18 |
4 |
AS |
$21.18 |
$47,657 |
D/D |
(2,250) |
1,609 |
|
- |
|
Niven Ralph |
Chief Scientific Officer |
|
2022-08-18 |
4 |
OE |
$1.74 |
$4,555 |
D/D |
2,250 |
3,859 |
|
- |
|
Dake Benjamin T |
See Remarks |
|
2022-08-16 |
4 |
AS |
$22.44 |
$482,932 |
D/D |
(21,000) |
0 |
|
- |
|
Dake Benjamin T |
See Remarks |
|
2022-08-16 |
4 |
OE |
$1.74 |
$36,540 |
D/D |
21,000 |
21,000 |
|
- |
|
Dake Benjamin T |
See Remarks |
|
2022-08-11 |
4 |
AS |
$23.89 |
$32,232 |
D/D |
(1,347) |
0 |
|
- |
|
Dake Benjamin T |
See Remarks |
|
2022-08-11 |
4 |
OE |
$1.74 |
$2,344 |
D/D |
1,347 |
1,347 |
|
- |
|
Dake Benjamin T |
See Remarks |
|
2022-08-10 |
4 |
AS |
$24.06 |
$306,366 |
D/D |
(12,720) |
0 |
|
- |
|
Dake Benjamin T |
See Remarks |
|
2022-08-10 |
4 |
OE |
$1.74 |
$22,133 |
D/D |
12,720 |
12,720 |
|
- |
|
Dake Benjamin T |
See Remarks |
|
2022-08-09 |
4 |
AS |
$23.84 |
$209,325 |
D/D |
(8,700) |
0 |
|
- |
|
Dake Benjamin T |
See Remarks |
|
2022-08-09 |
4 |
OE |
$1.74 |
$15,138 |
D/D |
8,700 |
8,700 |
|
- |
|
Dake Benjamin T |
See Remarks |
|
2022-08-08 |
4 |
AS |
$24.39 |
$170,962 |
D/D |
(6,943) |
0 |
|
- |
|
Dake Benjamin T |
See Remarks |
|
2022-08-08 |
4 |
OE |
$1.74 |
$12,081 |
D/D |
6,943 |
6,943 |
|
- |
|
Atlas Venture Fund Xii, L.p. |
10% Owner |
|
2022-07-15 |
4 |
AS |
$0.00 |
$0 |
D/D |
(310,388) |
2,327,909 |
|
- |
|
Atlas Venture Fund Xii, L.p. |
10% Owner |
|
2022-04-01 |
4 |
AS |
$0.00 |
$0 |
D/D |
(465,582) |
2,638,297 |
|
- |
|
Cormorant Private Healthcare Fund Ii, Lp |
Former 10% Owner |
|
2021-07-02 |
4 |
B |
$14.00 |
$7,000,000 |
I/I |
500,000 |
2,030,691 |
0.01 |
- |
|
Cormorant Private Healthcare Fund Ii, Lp |
Former 10% Owner |
|
2021-07-02 |
4 |
A |
$0.00 |
$0 |
I/I |
1,530,691 |
1,530,691 |
|
- |
|
Grayzel David S. |
Director |
|
2021-07-02 |
4 |
B |
$14.00 |
$7,499,996 |
I/I |
535,714 |
3,103,879 |
2.1 |
- |
|
Grayzel David S. |
Director |
|
2021-07-02 |
4 |
A |
$0.00 |
$0 |
I/I |
2,568,165 |
2,568,165 |
|
- |
|
Atlas Venture Associates Xii, Llc |
10% Owner |
|
2021-07-02 |
4 |
B |
$14.00 |
$7,499,996 |
D/D |
535,714 |
3,103,879 |
2.45 |
- |
|
232 Records found
|
|
Page 9 of 10 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|